NEW YORK (CNN/Money) - About 1,000 pages of documents detailing Martha Stewart's phone calls and e-mails have been delivered to a congressional panel looking into whether the high-profile CEO illegally profited from insider information on ImClone Systems.

The documents from Stewart, as well as those of her business manager, have been delivered to the Rayburn House Office Building, where the Committee on Energy and Commerce has its offices.

A spokesperson for Rep. James Greenwood, a Pennsylvania Republican who chairs the House Energy and Commerce investigative subcommittee, said staffers are reviewing the documents to confirm that Stewart has fully complied with their request.

Stewart sold nearly 4,000 shares of ImClone stock on December 27, when its shares closed at $58.30. They began tumbling the next day when the Food and Drug Administration declined to approve Erbitux, ImClone's much-anticipated cancer drug.

Stewart has denied she had any insider knowledge of the news, saying she had a long-standing agreement with her broker to sell ImClone shares when they hit a certain price.

But her level of cooperation apparently frustrated lawmakers, at least prior to the delivery of documents Tuesday afternoon. The committee had asked for records of all Stewart's phone calls and e-mails between Dec. 1 and Jan. 9 related to ImClone, to Sam Waksal, the former ImClone CEO who is friends with Stewart, and to her Merrill Lynch securities account.

Waksal pled innocent earlier this month to federal charges related to insider trading. According to that indictment, Waksal secretly advised two family members to sell ImClone shares ahead of the FDA news.

Greenwood had raised the threat of a subpoena. That decision could come by Labor Day, he said.

"I'd rather not subpoena Ms. Stewart," Greenwood told CNN/Money earlier Tuesday. "I've extended an invitation to talk with our investigators. I said we'd do that in the place of her choosing in a nonpublic way without advance notice to the press so we wouldn't have paparazzi there. But she's declined to do that."

Calling Stewart, who runs a media company focusing on homemaking and design, before Congress would draw intense public scrutiny.

Before seeing the latest documents, Greenwood said his investigators have found no evidence to support Stewart's claim that the sale of the shares was triggered by a pre-arranged "stop-loss" arrangement with her broker.

He also said investigators will be looking through the information Stewart is providing to see if there is evidence she knew of the pending FDA action or the sale of family shares by Samuel Waksal.

Shares of Stewart's company, Martha Stewart Living Omnimedia (MSO: Research, Estimates), rose 91 cents to $9.05 Tuesday, narrowing their year-to-date loss to 45 percent. They've held up better than ImClone (IMCL: Research, Estimates), which is off 82 percent this year.